Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-650 (infliximab) in active ulcerative colitis
jRCT2080220293Phase 3
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of infliximab in autoimmune colitis, sponsored by Mitsubishi Tanabe Pharma Corporation.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080220293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220293.